---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009691"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:46:16.817704+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics FY2023 net loss $46.5M; raised $177.2M in Q1 2024 financings

## Summary
- Net loss $46.5M ($0.17/share) vs $10.8M ($0.08) in FY2022; R&D expenses surged to $21.3M from $0.9M.
- Cash $9.2M at Dec 31, 2023; subsequent private placements & public offering raised ~$177.2M gross in Q1 2024.
- Phase 1/2a trials for [212Pb]VMT-α-NET (NETs) and [212Pb]VMT01 (melanoma) advanced; Cohort 2 enrolling.
- Entered collaboration with Bristol Myers Squibb for VMT01+nivolumab combo; Lantheus gets option for VMT-α-NET license.
- Acquired radiopharmaceutical manufacturing facility in Somerset, NJ; sold brachytherapy business to GT Medical.

## SEC filing metadata
- accession: 0001437749-24-009691
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/0001437749-24-009691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/isr20240327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009691
- JSON: https://secwatch.observer/filing/0001437749-24-009691.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009691.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/0001437749-24-009691-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.